Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF
0
FDA Orange Book
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Myoflex
2. Triethanolamine Salicylate
1. Triethanolamine Salicylate
2. 2174-16-5
3. Tea-salicylate
4. Neo Heliopan Ts
5. Tea Salicylate
6. Neotan W
7. Salicylic Acid Trolamine
8. H8o4040bhd
9. 2-hydroxybenzoic Acid, Compd. With 2,2',2''-nitrilotris(ethanol) (1:1)
10. Trolamine Salicylate (usp)
11. Trolamine Salicylate [usp]
12. Benzoic Acid, 2-hydroxy-, Compd. With 2,2',2''-nitrilotris(ethanol) (1:1)
13. Arthricream
14. Myoflex
15. Sunarome W
16. Benzoic Acid, 2-hydroxy-, Compd. With 2,2',2''-nitrilotris[ethanol] (1:1)
17. Arthricream (tn)
18. Dsstox_cid_27945
19. Dsstox_rid_82697
20. Unii-h8o4040bhd
21. Dsstox_gsid_47969
22. Schembl15847
23. Salicylic Acid Triethanolamine
24. Tea-salicylate [inci]
25. Chembl2107288
26. Dtxsid4047969
27. 2-[bis(2-hydroxyethyl)amino]ethanol;2-hydroxybenzoic Acid
28. Triethanolamine, Salicylate
29. Salicylic Acid Triethanolamine Salt
30. Einecs 218-531-3
31. Tox21_201084
32. Trolamine Salicylate [mart.]
33. Trolamine Salicylate [who-dd]
34. Db11079
35. Triethanolamine Salicylate [mi]
36. Ncgc00248985-01
37. Ncgc00258636-01
38. Triethanolamine Salicylate [vandf]
39. Cas-2174-16-5
40. Trolamine Salicylate [usp Impurity]
41. Trolamine Salicylate [usp Monograph]
42. Ft-0708839
43. 2,2',2''-nitrilotriethanol 2-hydroxybenzoate
44. D08501
45. Q7845153
46. Salicylic Acid, Compound With 2,2',2''-nitrilotriethanol (1:1)
Molecular Weight | 287.31 g/mol |
---|---|
Molecular Formula | C13H21NO6 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 7 |
Exact Mass | 287.13688739 g/mol |
Monoisotopic Mass | 287.13688739 g/mol |
Topological Polar Surface Area | 122 Ų |
Heavy Atom Count | 20 |
Formal Charge | 0 |
Complexity | 189 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Indicated for the temporary relief of aches, and pains of muscles and joints associated with backache, lumbago, strains, bruises, sprains and arthritic or rheumatic pain, pain of tendons and ligaments.
Trolamine salicylate is a salicylate that inhibits cyclo-oxygenase (COX) enzymes responsible for generating pro-inflammatory factors such as to induce pain and inflammation. It is thought to mediate its analgesic effect through inhibition of COX-2 enzyme, which is an induced enzyme responsible for inflammatory responses and pain in muscle and joint disorders. By inhibiting fatty acid COX enzyme, trolamine salicylate inhibits the production of prostaglandins and thromboxanes in inflammatory cells involved in generating pain and inflammation. It thereby works to temporarily reduce mild to moderate pain. In subjects with muscle soreness from exercise, administration of topical trolamine salicylate was associated with reduced duration and severity of muscule soreness compared to placebo. In subjects with osteoarthritis in hands, trolamine salicylate cream was shown to be effective in achieving temporary relief of minor pain and stiffness.
Absorption
Following topical administration of 10% trolamine salicylate in healthy volunteers, salicylic acid could not be detected in serum indicating low systemic absorption.
Route of Elimination
Following topical administration of 10% trolamine salicylate in healthy volunteers, urinary recovery of total salicylate during the first 24 hours was 6.9 mg (p < 0.05), which is 1.4% of total dose.
Volume of Distribution
Topical administration of 1 gram of 10% trolamine salicylate in abdominal rat skin resulted in an approximate extravascular volume of distribution (V/F) of 24.0 mL.
Inflammation and tissue damage in different conditions including arthritis, bursitis, joint disorder, bruises, and strains or sprains of muscle origin, induce mild to moderate pain and are associated with increase prostaglandin synthesis. This is thought to be a result of COX-2 enzyme induction. COX-2 is induced in inflammatory cells in case of cell injury, infection or activation from inflammatory cytokines such as interleukin (IL)-1 and tumor necrosis factor (TNF)-. Upon activation, COX-2 produces prostanoid mediators of inflammation such as prostaglandins and thromboxanes. Trolamine salicylate mediates its analgesic effect by inhibiting the production of inflammatory mediators that sensitize nociceptive nerve endings and generate pain.
Related Excipient Companies
Excipients by Applications
Market Place
ABOUT THIS PAGE
65
PharmaCompass offers a list of Triethanolamine Salicylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Triethanolamine Salicylate manufacturer or Triethanolamine Salicylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Triethanolamine Salicylate manufacturer or Triethanolamine Salicylate supplier.
PharmaCompass also assists you with knowing the Triethanolamine Salicylate API Price utilized in the formulation of products. Triethanolamine Salicylate API Price is not always fixed or binding as the Triethanolamine Salicylate Price is obtained through a variety of data sources. The Triethanolamine Salicylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Triethanolamine Salicylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Triethanolamine Salicylate, including repackagers and relabelers. The FDA regulates Triethanolamine Salicylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Triethanolamine Salicylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Triethanolamine Salicylate supplier is an individual or a company that provides Triethanolamine Salicylate active pharmaceutical ingredient (API) or Triethanolamine Salicylate finished formulations upon request. The Triethanolamine Salicylate suppliers may include Triethanolamine Salicylate API manufacturers, exporters, distributors and traders.
Triethanolamine Salicylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Triethanolamine Salicylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Triethanolamine Salicylate GMP manufacturer or Triethanolamine Salicylate GMP API supplier for your needs.
A Triethanolamine Salicylate CoA (Certificate of Analysis) is a formal document that attests to Triethanolamine Salicylate's compliance with Triethanolamine Salicylate specifications and serves as a tool for batch-level quality control.
Triethanolamine Salicylate CoA mostly includes findings from lab analyses of a specific batch. For each Triethanolamine Salicylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Triethanolamine Salicylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Triethanolamine Salicylate EP), Triethanolamine Salicylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Triethanolamine Salicylate USP).